• The Strength At The Interface: Academia Meets Biopharma Industry

    Collaborations between academia and industry are becoming more common as biopharma companies, both large and small, see the value gained from different approaches.

  • Why You Should Consider Automated In Vivo Sampling Systems

    While in vitro studies are becoming more accurate and the resulting preclinical data more likely to predict the clinical activity of a drug, in vivo studies (studies in animals) are still vital for the assessment of pharmacokinetics and drug metabolism and essential for approval of drugs and devices by regulatory bodies. By Suzanne Elvidge, Life Science Leader magazine

  • The Next Biopharma Business Model

    One of the biggest costs for the biopharma industry is that of drug R&D. “I’ve worked in the biopharma industry for more than 25 years, and I felt that the R&D sector was underperforming,” says Ulrich Grau, Ph.D., president, CEO, and cofounder of Lux Biosciences. By Suzanne Elvidge, Life Science Leader magazine

  • The Falsified Medicines Directive – What Does It Really Mean?

    The trade in falsified medicines — medicines that look real but really aren’t what they seem — is a huge and growing one, and it is putting patients’ health and even their lives at risk. Along with regulatory authorities around the world, the European Union is putting directives into place that could begin to slow this deadly trade.

Suzanne Elvidge

Suzanne Elvidge